Cargando…

Effects of rivastigmin tartarat in the therapy of patients with schizophrenia

Detalles Bibliográficos
Autores principales:	Djordjevic, Snezana, Japalak, Snezana, Vidojevic, Vera
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992008/ http://dx.doi.org/10.1186/1744-859X-9-S1-S91

Ejemplares similares

Adverse drug reactions and polypharmacy in cardiac patients
por: Mugoša, Snežana, et al.
Publicado: (2012)

Potentially inappropriate medication use in the elderly in Montenegro
por: Rolevski, Marta, et al.
Publicado: (2012)

Esophagectasis Related to Rivastigmine
por: Sasaki, Osamu, et al.
Publicado: (2019)

The effect of psychopathology on set shifting and reversal learning in schizophrenia
por: Theochari, Eirini, et al.
Publicado: (2010)

Rivastigmine in the treatment of patients with Alzheimer’s disease
por: Müller, Thomas
Publicado: (2007)

EPA in schizophrenia and violence
por: Treasaden, Ian H
Publicado: (2010)

Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study
por: Tsuno, Norifumi, et al.
Publicado: (2019)

European Treatment Guidelines for schizophrenia
por: Gaebel, Wolfgang
Publicado: (2010)

Medical care and long-term treatment of patients with schizophrenia: ethical concerns
por: do Couto, Frederico Simões
Publicado: (2010)

Adverse event occurrence and treatment change in patients with schizophrenia; the GRACE study
por: Karadima, Dimitra, et al.
Publicado: (2010)

Increased metabolic and cardiovascular morbidity in patients with schizophrenia: recommendation for diagnoses and treatment
por: Cohen, Dan
Publicado: (2010)

A ten-year-analysis of cardiopulmonary resuscitations in Celje emergency medical service
por: Kajba, S, et al.
Publicado: (1998)

Rivastigmine in Chinese patients with subcortical vascular dementia
por: Mok, Vincent, et al.
Publicado: (2007)

Simple schizophrenia: case report and review of the literature
por: Efstratiou, Sofia, et al.
Publicado: (2010)

Rivastigmine in the treatment of Alzheimer’s disease: an update
por: Onor, Maria Luisa, et al.
Publicado: (2007)

Acquired Localized Hypertrichosis Induced by Rivastigmine
por: Imbernón-Moya, Adrian, et al.
Publicado: (2016)

Polypharmacy in schizophrenia - therapeutic option or a sign of despair?
por: Konstantinidis, Anastasios
Publicado: (2010)

Facial emotion recognition in schizophrenia: neuropsychological and psychosocial correlates
por: Jaracz, Jan, et al.
Publicado: (2010)

The relationship between visual memory and the P300 in families with schizophrenia
por: Pentaraki, Alexandra, et al.
Publicado: (2010)

Relationship of parental age with set shifting and reversal learning in schizophrenia
por: Kontis, Dimitrios, et al.
Publicado: (2010)

The effect of single and repeated doses of rivastigmine on gastric myoelectric activity in experimental pigs
por: Tsianou, Chrysostomi Christina, et al.
Publicado: (2023)

Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2017)

Brain cell membrane motion-restricted phospholipids in patients with schizophrenia who have seriously and dangerously violently offended
por: Puri, Basant K, et al.
Publicado: (2010)

Why treating early, treating well, and treating for life is important in schizophrenia
por: Kahn, Rene
Publicado: (2010)

Subjective health definition and health behaviors in persons suffering from schizophrenia
por: Dutczak, Beata, et al.
Publicado: (2010)

Thirty-day hospital re-admission for Medicaid enrollees with schizophrenia: the role of patient comorbidity and local health-care systems
por: Busch, Alisa B, et al.
Publicado: (2015)

The role of RLAI in early schizophrenia treatment: critical aspects regarding efficacy and safety
por: Papageorgiou, George
Publicado: (2010)

Hemodynamic effects of kinetic therapy in critically ill trauma patients
por: Stiletto, R, et al.
Publicado: (1997)

Haemodynamic effects of kinetic therapy in critically ill trauma patients
por: Stiletto, R, et al.
Publicado: (1997)

Increased levels of ethane, a non-invasive, quantitative, direct marker of n-3 lipid peroxidation, in the breath of patients with schizophrenia
por: Puri, Basant K, et al.
Publicado: (2010)

An Atypical Cutaneous Reaction to Rivastigmine Transdermal Patch
por: Grieco, T., et al.
Publicado: (2011)

Rivastigmine for the treatment of dementia associated with Parkinson’s disease
por: Reingold, Jennifer L, et al.
Publicado: (2007)

Direct Asymmetric Reductive Amination for the Synthesis of (S)-Rivastigmine
por: Gao, Guorui, et al.
Publicado: (2018)

Treatment of pediatric antimuscarinic delirium with oral rivastigmine
por: Yakey, Brandtly, et al.
Publicado: (2023)

Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson’s Disease Dementia
por: Oh, Yoon-Sang, et al.
Publicado: (2015)

Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice
por: Kondak, Constantin, et al.
Publicado: (2023)

The neurobiology of subjective tolerability to antipsychotic medications in Schizophrenia - is it also relevant to the genesis of comorbid addiction?
por: Awad, George
Publicado: (2010)

Improving mental health policy in the case of schizophrenia in Thailand: evidence-based information for efficient solutions
por: Phanthunane, Pudtan, et al.
Publicado: (2012)

Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer’s disease
por: Kano, Osamu, et al.
Publicado: (2013)

The Effect of Rivastigmine Transdermal Patch on Sleep Apnea in Patients with Probable Alzheimer's Disease
por: Kim, Hyeyun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0121aphdcju68htiat0572eg9s